Alyssa M Schlenz1,2, Shannon Phillips3, Martina Mueller3,4, Cathy Melvin4, Robert J Adams5, Julie Kanter6. 1. Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina. 2. Section of Developmental Pediatrics, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado. 3. College of Nursing, Medical University of South Carolina, Charleston, South Carolina. 4. Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina. 5. Department of Neurology and Neurosurgery, Medical University of South Carolina, Charleston, South Carolina. 6. Division of Hematology & Oncology, University of Alabama Birmingham, Birmingham, Alabama.
Abstract
BACKGROUND: Children with sickle cell anemia (SCA) are at increased risk for stroke. In 2014, the National Heart, Lung, and Blood Institute (NHLBI) developed guidelines for stroke prevention in SCA informed by the Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP II) trials. The guidelines specify the use of transcranial Doppler (TCD) screening and intervention with chronic red cell transfusions (CRCT) in children with SCA who have TCD indication of high stroke risk. The purpose of this study was to describe real-world practice patterns of stroke risk screening and intervention in sites that participated in the Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) Consortium. PROCEDURE: Site investigators completed a survey during the formative stages of the study to evaluate their TCD practices relative to the STOP studies. Descriptive statistics and analysis of free-text comments for more complex practices were evaluated. RESULTS: Results suggested universal acceptance of annual TCD screening and initiation of CRCT following an abnormal result among the DISPLACE Consortium, consistent with NHLBI recommendations. However, there was wide variation in methods for conducting TCD screenings (eg, dedicated Doppler vs TCD imaging), classifying TCD results, and actions taken for conditional and inadequate results. CONCLUSIONS: Annual TCD screening and initiation of CRCT are critical stroke prevention practices that were universally embraced in the consortium. Additional research would be beneficial for informing clinical practices for areas in which guidelines are absent or unclear.
BACKGROUND:Children with sickle cell anemia (SCA) are at increased risk for stroke. In 2014, the National Heart, Lung, and Blood Institute (NHLBI) developed guidelines for stroke prevention in SCA informed by the Stroke Prevention Trial in Sickle Cell Anemia (STOP) and Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP II) trials. The guidelines specify the use of transcranial Doppler (TCD) screening and intervention with chronic red cell transfusions (CRCT) in children with SCA who have TCD indication of high stroke risk. The purpose of this study was to describe real-world practice patterns of stroke risk screening and intervention in sites that participated in the Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) Consortium. PROCEDURE: Site investigators completed a survey during the formative stages of the study to evaluate their TCD practices relative to the STOP studies. Descriptive statistics and analysis of free-text comments for more complex practices were evaluated. RESULTS: Results suggested universal acceptance of annual TCD screening and initiation of CRCT following an abnormal result among the DISPLACE Consortium, consistent with NHLBI recommendations. However, there was wide variation in methods for conducting TCD screenings (eg, dedicated Doppler vs TCD imaging), classifying TCD results, and actions taken for conditional and inadequate results. CONCLUSIONS: Annual TCD screening and initiation of CRCT are critical stroke prevention practices that were universally embraced in the consortium. Additional research would be beneficial for informing clinical practices for areas in which guidelines are absent or unclear.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: J Krejza; W Rudzinski; M A Pawlak; M Tomaszewski; R Ichord; J Kwiatkowski; D Gor; E R Melhem Journal: AJNR Am J Neuroradiol Date: 2007-09 Impact factor: 3.825
Authors: Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella Journal: N Engl J Med Date: 2014-08-21 Impact factor: 91.245
Authors: James F Casella; Allison A King; Bruce Barton; Desiree A White; Michael J Noetzel; Rebecca N Ichord; Cindy Terrill; Deborah Hirtz; Robert C McKinstry; John J Strouse; Thomas H Howard; Thomas D Coates; Caterina P Minniti; Andrew D Campbell; Bruce A Vendt; Harold Lehmann; Michael R Debaun Journal: Pediatr Hematol Oncol Date: 2010-03 Impact factor: 1.969
Authors: Janet L Kwiatkowski; Suzanne Granger; Donald J Brambilla; R Clark Brown; Scott T Miller; Robert J Adams Journal: Br J Haematol Date: 2006-08 Impact factor: 6.998
Authors: Robert J Adams; Dan T Lackland; Lynette Brown; David Brown; Jenifer Voeks; Heather J Fullerton; Julie Kanter; Janet L Kwiatkowski Journal: Am J Hematol Date: 2016-10-25 Impact factor: 10.047
Authors: Jane S Hankins; Gail L Fortner; M Beth McCarville; Matthew P Smeltzer; Winfred C Wang; Chin-Shang Li; Russell E Ware Journal: Br J Haematol Date: 2008-05-08 Impact factor: 6.998
Authors: Julie Kanter; Shannon Phillips; Alyssa M Schlenz; Martina Mueller; Mary Dooley; Logan Sirline; Robert Nickel; Robert Clark Brown; Lee Hilliard; Cathy L Melvin; Robert J Adams Journal: J Pediatr Hematol Oncol Date: 2021-11-01 Impact factor: 1.289